

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: **Kapil N. Bhalla et al.**  
SERIAL NO.: **10/605,283** ART UNIT: **1614**  
FILING DATE: **09/19/2003** EXAMINER: **DONNA A. JAGOE**  
FOR: **Suberoylanilide Hydromaxic Acid Treatment of Leukemia Cells**

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL OF REQUEST FOR CORRECTION**

Sir,

Please accept the enclosed:

1. Applicant's Request for Correction of Filing Receipt; and
2. A copy of the filing receipt received by counsel.

Very respectfully,  
**SMITH & HOPEN, P.A.**  
/thomas e toner/

---

Thomas E. Toner  
Reg. No.: 57,422  
180 Pine Avenue North  
Oldsmar, Florida 34677  
(813) 925-8505  
Attorneys for Applicant

---

**CERTIFICATE OF ELECTRONIC TRANSMISSION**  
(37 C.F.R. 2.190 (b))

I HEREBY CERTIFY that this correspondence is being electronically transmitted to the Patent and Trademark Office through EFS Web on March 25, 2009.

Date: March 25, 2009

/lauren reeves/

---

Lauren Reeves

Docket No. 1372.76.PRC

**PATENTS**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
                    **KAPIL N. BHALLA ET AL.** )  
Serial No.:     **10/605,283** )     Art Unit:   **1614**  
                    )     Examiner:   **Donna A. Jagoe**  
Filed:           **09/19/2003** )  
For:     **SUBEROYLANILIDE HYDROMAXIC** )  
          **ACID TREATMENT OF LEUKEMIA**  
          **CELLS**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTION OF FILING RECEIPT**

Sir:

We are in receipt of the attached Filing Receipt for the above-referenced application. We have compared the Filing Receipt with a copy of the application we have retained in our records and have determined that certain information was incorrectly entered into the PTO's system. The undersigned hereby requests that the Title be changed on the filing receipt and in the record of the above-mentioned application as follows:

*Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate*  
should be changed to  
*Suberoylanilide Hydroxmaxic Acid Treatment of Leukemia Cells*

A copy of the original filing receipt is enclosed. The issuance of a corrected filing receipt is respectfully requested.

Respectfully submitted,

/thomas e toner/

Reg. No. 57,422  
Tel. No.: (813) 925-8505

**SIGNATURE OF PRACTITIONER**  
Thomas E. Toner  
Smith & Hopen, P.A.  
180 Pine Avenue North  
Oldsmar, FL 34677

**CERTIFICATE OF ELECTRONIC TRANSMISSION**  
**(37 C.F.R. 2.190 (b))**

I HEREBY CERTIFY that this correspondence is being electronically transmitted to the Patent and Trademark Office through EFS Web on March 25, 2009.

Date: March 25, 2009

/lauren reeves/

Lauren Reeves



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FILE FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/605,283	09/19/2003	3679	375	1372.76.PRC	3	16	3

21901  
 SMITH & HOPEN PA  
 15950 BAY VISTA DRIVE  
 SUITE 220  
 CLEARWATER, FL 33760

CONFIRMATION NO. 2282

## UPDATED FILING RECEIPT



\*OC000000012152700\*

Date Mailed: 03/22/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Kapil N. Bhalla, Tampa, FL;  
 Ramadevi Nimmanapalli, Tampa, FL;

## Assignment For Published Patent Application

UNIVERSITY OF SOUTH FLORIDA, Tampa, FL;

## Domestic Priority data as claimed by applicant

This appln claims benefit of 60/319,563 09/19/2002

## Foreign Applications

If Required, Foreign Filing License Granted: 12/04/2003

Projected Publication Date: 07/01/2004

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Suberoylanilide Hydroxamic Acid  
 Treatment of Leukemia Cells

~~Method of Treating Leukemia with a Combination of Suberoylanilide Hydroxamic Acid and Imatinib Mesylate~~

Preliminary Class

403

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).